These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35280743)

  • 1. NCAPG as a Novel Prognostic Biomarker in Glioma.
    Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
    Front Oncol; 2022; 12():831438. PubMed ID: 35280743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma.
    Xu Z; Xu H; Chen X; Huang X; Tian J; Zhao J; Liu B; Shi F; Wu J; Pu J
    Onco Targets Ther; 2023; 16():819-837. PubMed ID: 37873495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRPS23 is a novel prognostic biomarker and promotes glioma progression.
    Wang Q; Chen G; Liu L; Peng X; Yang X; Yang L; Li C
    Aging (Albany NY); 2024 Jan; 16(3):2457-2474. PubMed ID: 38301044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma.
    Zheng G; Han T; Hu X; Yang Z; Wang J; Wen Z; Li H; Wang H
    Front Oncol; 2022; 12():770628. PubMed ID: 35372056
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
    Front Immunol; 2022; 13():974346. PubMed ID: 36275718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
    Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
    Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
    Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
    Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
    J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The N6-Methylandenosine-Related Gene
    Jiang X; Shi Y; Chen X; Xu H; Huang X; Li L; Pu J
    Front Mol Biosci; 2022; 9():773662. PubMed ID: 35309512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
    Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
    Front Oncol; 2021; 11():611038. PubMed ID: 33937022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
    Lv L; Zhang Y; Zhao Y; Wei Q; Zhao Y; Yi Q
    Front Cell Neurosci; 2021; 15():704344. PubMed ID: 34335194
    [No Abstract]   [Full Text] [Related]  

  • 18. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNPY4 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in gliomas.
    Li JW; Huang QR; Mo LG
    Medicine (Baltimore); 2022 Aug; 101(33):e30044. PubMed ID: 35984129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
    Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
    Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.